Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial-Reference-Cited by-同舟云学术

Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial

Published:2016-02 Issue:2 Volume:3 Page:e87-e98
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Nakamura Ryotaro,Rosa Corinna La,Longmate Jeffrey,Drake Jennifer,Slape Cynthia,Zhou Qiao,Lampa Melanie G,O'Donnell Margaret,Cai Ji-Lian,Farol Len,Salhotra Amandeep,Snyder David S,Aldoss Ibrahim,Forman Stephen J,Miller Jeffrey S,Zaia John A,Diamond Don J

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Hematology

Reference36 articles.

1. Immune reconstitution after hematopoietic cell transplantation;Bosch;Curr Opin Hematol,2012

2. Cytomegalovirus in hematopoietic stem cell transplant recipients;Ljungman;Hematol Oncol Clin North Am,2011

3. Early CMV reactivation still remains a cause of increased transplant related mortality in the current era: a CIBMTR analysis;Ramanathan;Blood,2014

4. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation;Green;Biol Blood Marrow Transplant,2012

5. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation;Peggs;Clin Infect Dis,2009

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation;Viruses;2024-08-08

2. Therapeutic vaccines for herpesviruses;Journal of Clinical Investigation;2024-05-01

3. A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant;Haematologica;2024-02-08

4. Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival;Transplantation and Cellular Therapy;2024-01

5. Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management. A report from the CMV International Symposium 2023;Transplant Infectious Disease;2023-11-09